Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
This article was originally published in The Pink Sheet Daily
Executive Summary
First quarter sales of $16m are the first time Amgen has split out sales of its PCSK9 inhibitor, has slight lead over competitor Praluent from Sanofi/Regeneron.